Observational studies - should we simply ignore them in assessing transfusion outcomes? by unknown
DEBATE Open Access
Observational studies - should we simply
ignore them in assessing transfusion
outcomes?
Kevin Trentino1, Shannon Farmer2,3* , Irwin Gross4, Aryeh Shander5 and James Isbister6
Abstract
Background: As defined by evidence-based medicine randomized controlled trials rank higher than observational
studies in the hierarchy of clinical research. Accordingly, when assessing the effects of treatments on patient
outcomes, there is a tendency to focus on the study method rather than also appraising the key elements of study
design. A long-standing debate regarding findings of randomized controlled trials compared with those of
observational studies, their strengths and limitations and questions regarding causal inference, has recently come
into focus in relation to research assessing patient outcomes in transfusion medicine.
Discussion: Observational studies are seen to have limitations that are largely avoided with randomized controlled
trials, leading to the view that observational studies should not generally be used to inform practice. For example,
observational studies examining patient outcomes associated with blood transfusion often present higher estimates
of adverse outcomes than randomized controlled trials. Some have explained this difference as being a result of
observational studies not properly adjusting for differences between patients transfused and those not transfused.
However, one factor often overlooked, likely contributing to these variances between study methods is different
exposure criteria. Another common to both study methods is exposure dose, specifically, measuring units
transfused during only a part of the patient’s hospital stay.
Summary: When comparing the results of observational studies with randomized controlled trials assessing
transfusion outcomes it is important that one consider not only the study method, but also the key elements of
study design. Any study, regardless of its method, should focus on accurate measurement of the exposure and
outcome variables of interest. Failure to do so may subject the study, regardless of its type, to bias and the need to
interpret the results with caution.
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Background
What is the current problem?
The results of randomized controlled trials (RCTs) are
not always consistent with the results of observational
studies, often leading to much debate [1–3]. RCTs rank
higher in the hierarchy of clinical research than obser-
vational studies and this could lead some to assume
that observational studies should not be used to inform
practice [4]. Some have suggested that observational
studies overestimate treatment effects and provide mis-
leading conclusions [1, 5–7].
What is the prejudice against observational studies?
It is generally believed that observational studies cannot
establish causation. They are considered susceptible to
unidentified confounders and prone to overestimate
treatment benefit and harm. Different results between
RCTs and observational studies are cited as examples.
Are the prejudices justified?
In a two-part series of articles in The New England Jour-
nal of Medicine the authors compared results from
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RCTs with observational studies. Interestingly, neither
article found evidence to support the claim that the re-
sults of observational studies are inferior to, or likely to
vary widely from, the results of RCTs [4, 8].
Dismissing observational studies based on study type
(or study method) alone is short-sighted. The view that
observational studies play no role in establishing causality is
invalid, especially when conducting an RCT is impossible
(e.g. smoking vs no smoking), unethical (e.g. comparing
transfusion with no transfusion in critical haemorrhage), lo-
gistically impossible (eg a very large trial investigating all-
comers regardless of age and multiple co-morbidities and
multiple intervention outcomes), or equipoise cannot be
clearly established. This is the case when it comes to asses-
sing patient outcomes associated with blood transfusion.
This article presents often overlooked factors likely to
contribute to the difference in results of observational
studies compared with RCTs evaluating the outcomes of
blood transfusion.
Discussion
How do observational studies compare with RCTs in
evaluating the outcomes of blood transfusion?
In 2008 a systematic review of the literature was conducted to
determine the relationship between red blood cell (RBC)
transfusion and patient outcomes in critically ill patients. The
pooled results from the observational studies found that RBC
transfusion was independently associated with higher odds of
mortality and higher odds of developing an infection [9].
The pooled results from these observational studies were
different from the pooled results from RCTs [10, 11]. For ex-
ample, the meta-analysis of observational studies found a 1.7
times higher odds of mortality in transfused patients (95 % CI
= 1.4–2.2) whereas a Cochrane review of RCTs found that lib-
eral transfusion was associated with a 1.3 times higher risk of
mortality (95%CI = 1.1–1.6) [12]. The pooled results from the
observational studies also found a 1.8 times higher risk of in-
fection in transfused patients (95 % CI = 1.5–2.2), higher than
the risk of infection with liberal transfusion reported in the
Rhode et al. review of RCTs (RR 1.2; 95%CI = 1.1–1.4) [13].
What is the reason for the apparent difference?
A reason commonly presented to explain this difference
is that observational studies are prone to bias because
transfused patients are sicker and therefore more likely
to have poorer outcomes [14, 15].
Many observational studies highlight that, on average,
patients transfused are older and have more comorbidi-
ties than patients not transfused. Few, if any, would
doubt that unless severity of illness is adjusted for, re-
sults will be confounded. However, there are two main
reasons why the observed differences between the re-
sults of observational studies and of RCTs are not com-
pletely explained by patients being sicker.
First, the observational studies included in the review con-
sistently adjusted for confounders [9]. For example, results of
12 different studies were pooled in the mortality analysis. All
12 of these pooled studies adjusted for confounders (Table 1).
These studies adjusted for a total of 167 confounders (me-
dian = 9) with a range of 3–30 confounders. When analysing
the confounders included in the 12 pooled studies, 11 in-
cluded age, 10 included gender and 6 included race. All stud-
ies attempted to adjust for the ‘sicker’ patient. For example,
all 4 of the mortality studies in trauma adjusted for the Injury
Severity Score and 3 of the 4 included the Glasgow Coma
Scale. To account for differences in patients presenting for
isolated coronary artery bypass graft (CABG) surgery, re-
searchers from the Cleveland Clinic included 29 confounders
“known to be associated with adverse outcome after CABG”
in their analysis.
Second, it isn’t always the sicker patient who is transfused.
Large, unexplained variability in transfusion practice exists
and has persisted for some time [16]. The decision to trans-
fuse is often based simply on a hemoglobin value predeter-
mined by the physician (independent of whether the patient
is male or female, despite having a different normal
hemoglobin value), without regard to the clinical or morbid
condition of the patient [17]. One study found that chronic
kidney disease alone, in the absence of anemia, was not an
independent predictor of transfusion in patients undergoing
major joint arthrosplasty. However, a low hemoglobin level
was independently associated with increased transfusion
utilization [18]. There are also differences in transfusion
rates by gender [19]. Additionally, a number of studies have
shown that transfusion is associated with worse outcomes in
less sick patients compared with those who are more sick
[20, 21]. For example, Ferraris and colleagues, assessing
transfusions and adverse surgical outcomes, found that pa-
tients at low risk for surgical morbidity or mortality had be-
tween an 8- and 10-fold excess risk of adverse outcomes
when they received a blood transfusion compared to high
risk patients [22]. These factors, and others discussed else-
where [23], suggest that the “sicker patient” hypothesis alone
is not sufficient to explain the differences between study
types and dismiss the findings of observational studies. Most
importantly, no one has identified the “missing” co-
morbidity of the “sicker patient” to explain the differences in
outcome between transfused and non-transfused patients.
How do the differences in exposure criteria affect the
analysis of results?
Another factor that may contribute to differences be-
tween pooled results of the observational studies and the
RCTs is that different exposure criteria were studied.
Hatala and colleagues described 4 key elements of study
design, namely (1) patients, (2) interventions (exposure),
(3) outcomes and (4) study methods [24]. The exposure
studied in the review of observational studies differed
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from the exposure studied in the review of RCTs
(Table 2). The meta-analysis of observational studies
sought to estimate the association between transfusion
versus no transfusion and outcomes. The meta-analysis
of RCTs looked at a liberal versus restrictive transfu-
sion threshold and outcomes. This is a critical distinc-
tion [4].
A 2015 systematic review and meta-analysis assessed
the outcomes of RCTs compared with observational
studies in cardiac surgery [25]. The forest plots for RCTs
and observational studies are both labelled “liberal trans-
fusion” vs “restrictive transfusion”. This could lead the
casual reader to conclude that both study methods used
the same exposure criteria. However, that is not the case.
The discussion states that the observational studies com-
pared transfusion with no transfusion. This is not liberal
vs restrictive. The accompanying editorial makes the
point that “These two assessments are not related in any
meaningful way [26].”
In simple terms, observational studies compare out-
comes in a group with a 100 % transfusion rate versus
those with 0 % transfusion. In restrictive versus liberal
transfusion RCTs, both groups contain a significant
number of patients exposed to transfusion. For example,
17 of the 19 trials included in the Cochrane Review
referred to earlier provided data on the proportion of pa-
tients transfused in both exposure groups. The patients
assigned to a liberal transfusion strategy had a pooled
transfusion rate of 84 %; patients in the restrictive trans-
fusion group had a transfusion rate of 46 %.
Given this key difference in study design one would
expect differences in results. One might expect that the
meta-analysis of observational studies, where the differ-
ence in transfusion rates between the two groups was
100 %, would produce a higher estimate than any study
comparing liberal to restrictive transfusion, where the
difference in transfusion rates is always less.
Are randomized controlled trials free from bias by
design?
An assumption often made is that any inherent con-
founding found in observational studies can be avoided
in RCTs [14, 27]. It is true that confounding can often
be limited through an RCT, but does this mean that all
RCTs are automatically free from bias?
In the pooled results from eleven trials comparing 30-
day mortality, two large studies - Transfusion Require-
ments in Critical Care (TRICC) and Liberal or Restrict-
ive Transfusion in High Risk Patients after Hip Surgery
Table 1 Adjustments included in the 12 pooled observational studies into RBC transfusions relationship with mortality
Studies analyzed listed by first author
Confounder Carson Corwin Croce Dunne Gong Janson Koch Malone Rao Silver-board Vincent Yang Total
Cardio-vascular comorbidities 6 1 1 9 13 13 43
Demographic/Socio-economic factors 5 2 3 3 2 3 3 4 2 1 5 33
Severity of disease scores 3 3 2 1 1 1 3 1 1 2 18
Other admission adjustments 6 3 1 1 1 12
Perioperative adjustments 3 3 5 11
Tests and procedure results 1 1 3 2 2 1 10
Hemoglobin/Hematocrit 2 2 1 1 1 1 8
Diabetes 1 2 1 1 5
Alcohol/Tobacco use 1 2 2 5
Medication 1 1 3 5
Renal comorbidities 1 1 1 1 4
Smoking status 1 1 2
Blood loss 1 1 2
Family history of disease 1 1 2
Other blood products 2 2
Respiratory comorbidities 1 1
Liver comorbidities 1 1
Pre-operative transfusion 1 1
Age of blood transfused 1 1
Septic shock 1 1
Total 30 3 7 5 18 8 29 9 28 4 4 22 167
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(FOCUS) - contributed 75 % of the weight in the mortal-
ity analysis [12].
These two trials reported consistent results - no
statistically significant difference in mortality between
the two groups studied. However, these trials both re-
corded a large number of RBC units transfused prior
to randomization. In the TRICC trial 1045 units were
transfused before the 418 patients were assigned to a
restrictive strategy, and 966 units to the 420 patients
eventually assigned to the liberal. In the FOCUS trial
531 units were transfused before the 1009 patients
were assigned to a restrictive strategy, with 452 units
to the 1007 patients eventually assigned to the liberal
group. These units are not included in the analysis of
the relationship of transfusion to outcomes and could
potentially introduce an inaccurate estimate of the ex-
posure’s effect on the risk of outcome.
Notwithstanding, these trials can answer important
questions. For intensive care physicians the TRICC trial
answers the question: Regardless of transfusions that
Table 2 The four key elements of study design applied to three systematic reviews of transfusion literature
Study 1. Patients 2. Intervention/Exposure 3. Outcomes 4. Study
methods
Efficacy of red blood cell transfusion in the
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for guiding
Transfusion thresholds and other strategies
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Orthopaedics Length of Stay













HealthCare–Associated Infection After Red
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Adapted from Hatala R, et al. Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to
combine their results. CMAJ : Canadian Medical Association journal 2005;172(5):661–5
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occur prior to the ICU, what might the impact be of a
restrictive transfusion threshold while in the ICU on
overall outcomes?
However, units transfused prior to randomization, and
any units transfused after discharge from ICU, limit the
generalization of outcome results. One cannot extend
the results and conclude that there is no difference in
patient outcome using a restrictive versus liberal transfu-
sion threshold in the patient’s entire episode of care. Nor
can one use these RCTs to compare the outcomes of
transfusion versus no transfusion.
One recent trial comparing liberal versus restrictive
transfusion thresholds did report a statistically signifi-
cant higher risk of death in the liberal transfusion group
[28]. This trial, studying patients with acute gastro-
intestinal bleeding, found an 82 % higher risk of death in
the liberal group within 45 days. This trial was different
from both the TRICC and FOCUS trials in at least one
key way: patients were randomized immediately after ad-
mission and anyone transfused within the previous
90 days was excluded.
Observational studies can also introduce bias from in-
accurate measurement of exposure variables. A study of
patients undergoing cardiac surgery compared outcomes
of those transfused with those not transfused [29]. Trans-
fusion was defined as blood administered within 24 h of
admission to ICU. Data suggest that 27 % of patients
undergoing cardiac surgery are transfused only in the op-
erating room [30] and it is possible that other patients
were transfused only outside the defined 24 h window. So
this study design likely misclassified a significant number
of patients who received transfusion as “not transfused”.
Any study, whether observational or RCT, that mea-
sures only the units transfused during a subpart of the
patient’s hospital stay, should be analyzed with caution.
This includes the many studies sourced from databases
that do not capture all transfusions a patient receives
during their hospitalization (e.g. studies using the ACS –
NSQIP database). Attempts to generalize the results to
transfusion’s association with overall outcomes will likely
underestimate the relationship.
RCTs have a number of limitations including tightly
defined patient populations, modest sample sizes and
short duration outcome measures [31]. Regarding the
latter, the Iowa trial found higher adverse neurological
events with restrictive transfusion thresholds in preterm
infants compared with liberal thresholds [32]. However,
a follow-up study of these infants at school age appeared
to contradict the early findings, demonstrating long-
term adverse effects on neurocognitive and academic
function associated with preterm liberal transfusion
thresholds [33].
Large prospective observational (phase 4 real-world)
studies play a major role not only in generating
hypotheses but unequivocally adding new knowledge to
the scientific literature. They assess large numbers of
diverse real-world patients with short-, mid- and long-
term follow-up. RCTs may be sufficient to establish
efficacy of a new intervention, but are often not large
enough to clearly identify harm [34]. Quality observa-
tional studies use a variety of sophisticated statistical
analyses, such as multi-variable regression modelling
and propensity score matching, in an effort to minimize
the potential for confounding. These studies, which
control for differences in patient groups, should not
simply be dismissed as biased but analyzed on their
scientific merit. Sir Austin Bradford Hill, pioneer of
the RCT, along with Sir Richard Doll, established the
causal link between tobacco use and lung cancer
without an RCT [35] and subsequently proposed 9
criteria for establishing causation from association.
Isbister and colleagues applied this to observational
literature on transfusion outcomes and found that all
criteria were met in relation to adverse outcomes as-
sociated with transfusion [36].
This issue is timely. “The naysayers continue to be-
lieve that only if they could find that one lost con-
founder that the multitude of agreeing papers would
be discredited, somehow making small transfusions an
improvement to outcome [37].” These recent com-
ments by Spiess highlight a recurring theme in
attitudes dismissive of the findings of observational
studies.
Conclusions
Observational studies examining the outcomes associ-
ated with transfusion often present higher estimates of
adverse events than RCTs. Some have argued this differ-
ence is because of the assumption that sicker patients
are transfused and observational studies cannot properly
adjust for this difference.
This explanation ignores other factors. It is not always
the sicker patient who is transfused. The difference be-
tween exposure criteria in observational studies and
RCTs limit comparison. Both observational studies and
RCTs measuring units transfused only during a subpart
of the patient’s hospital stay introduce bias.
Both RCTs and observational studies have strengths
and limitations and can be complementary in assessing
treatment effects. However, when comparing the results
of studies it is important the dialogue focuses not only
on the study method, but also on the key elements of
study design. Any study, whether RCT or observational,
should focus on accurate measurement of the exposure
and outcome variables of interest. A failure to do so po-
tentially exposes the study, regardless of its type, to bias
and the need to interpret the results with caution.
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